A Phase 3 interventional study of 5-Fluorouracil and Leucovorin in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 133 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-06-22.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 179 studies testing capecitabine in Colorectal Neoplasms — 24 open to participants now, 32 under way, 7 of them phase 3. Capecitabine · Colorectal Neoplasms.
Among the 179 studies testing capecitabine in Colorectal Neoplasms, this one is the 7th largest by enrollment of the 173 interventional ones that give a count, is the only one that started in 1998, is one of 32 in phase 3, and was the 2nd registered.
6,554 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.
Browse Colorectal Neoplasms studies →24 of the 179 studies testing capecitabine in Colorectal Neoplasms are open now, in 9 countries. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
Gruppo Oncologico del Nord-Ovest · Sites in France, Germany, Italy and 1 more country
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Nizhny Novgorod Regional Clinical Oncology Center · Sites in Russian Federation
Ages 70–90
Henry Ford Health System · Sites in United States
Ages 18+
By country, each count listing its studies:
Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
179 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 124 · Phase 3 37 · Phase 4 8
First in 1998; this study’s year is marked. 1 started in 1998.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,987 is above the median of 76 across 4,810 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 55 across the 173 interventional studies. Of the 111 that completed or were terminated, 36 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 179 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
111 studies in Colorectal Neoplasms by Hoffmann-La Roche: 3 open now, 6 under way, none of them phase 3. Of 100 finished, 52 (52%) have results posted.
Among the 111 studies in Colorectal Neoplasms by Hoffmann-La Roche, this one is the 3rd largest by enrollment of the 77 interventional ones that give a count, is the only one that started in 1998, is one of 15 in phase 3, and was the 1st registered.
Hoffmann-La Roche’s Colorectal Neoplasms studies by the year they started, since 1998.
9 of the studies testing capecitabine in Colorectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05700656The Netherlands Cancer InstituteGalunisertib Combined With Capecitabine in Advanced CRC With PM | 2026-12 |
| NCT06065371Henry Ford Health SystemSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | 2026-12 |
| NCT07229846Yanqiao ZhangA Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | 2027-02 |
| NCT07570914Tianjin Medical University Cancer Institute and HospitalHepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | 2027-05-30 |
| NCT07051785Liu HuangFruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer | 2027-07-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 179 studies testing capecitabine in Colorectal Neoplasms, from their registry updates:
Among Hoffmann-La Roche’s 111 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
This 2 arm study will compare the safety and efficacy of oral Xeloda, or 5-fluorouracil in combination with leucovorin, in patients who have undergone surgery for colon cancer. Patients will be randomized to receive either Xeloda 1250mg/m2 po bid on days 1-14 every 21 days, or leucovorin 20mg/m2 iv + 5-fluorouracil 425mg/m2 iv daily from day 1 to day 5 every 28 days. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received capecitabine 1250 milligram per square meter (mg/m \^ 2) orally, twice a day, for 14 days, followed by a 7-day rest period without treatment, as an intermittent therapy in a 3-week cycle for 8 cycles (24 weeks).
Drug: Capecitabine [Xeloda]
Participants received leucovorin 20 mg/m \^ 2 followed by 5-fluorouracil at 425 mg/m \^ 2, by rapid intravenous injection, daily, from Days 1 to 5 of the first week in each 4-week cycle for 6 cycles (24 weeks).
Drug: 5-Fluorouracil · Drug: Leucovorin
425mg/m2 iv daily from day 1 to day 5 every 28 days.
20mg/m2 iv daily from day 1 to day 5 every 28 days.
1250mg/m2 po bid on days 1-14 every 21 days.
Disease-free Survival
Participants with disease-free survival were reported. Disease-free survival was assessed as the number of days between randomization and the first time at which relapse, a new occurrence of colon cancer, or death was recorded, or the last time at which a participant was known to be disease free (censoring time).
Time frame: Approximately 3 years
Relapse-Free Survival
Participants with relapse-free survival were reported. Relapse-free survival was assessed as the number of days between randomization and the first time at which relapse, a new occurrence of colon cancer, or death was recorded, or the last time at which a participants was known to be disease free (censoring time), excluding deaths that were not related to treatment or to disease progression.
Time frame: Approximately 3 years
Overall Survival
Participants with overall survival were reported. Overall survival was assessed as the number of days between randomization and death or the last time at which a participant was known to be alive (censoring time).
Time frame: Approximately 3 years
Mean Change From Baseline in Global Health Status at Week 25
Global health status was assessed as a sub scale of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. It was scored on a scale of 0-100; where higher score indicates better quality of life. Wherever the scores for the participants were not available, the last value carried forward (LVCF) were used.
Time frame: Baseline (Days -7 to 1) and at Week 25
Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters
Laboratory abnormalities were categorized according to the National Cancer Institute of Canada Common Toxicity Criteria (NCIC - CTC) grading system (May 1991 revised) as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (life- threatening). Participants with abnormalities in hemoglobin, granulocytes, lymphocytes, neutrophils, neutrophils/granulocytes, platelets, white blood cell, potassium, serum creatinine, sodium, total bilirubin, alanine transaminase, aspartate aminotransferase, alkaline phosphatase, calcium (hyper), and calcium (hypo) with Grades 1-4 were presented.
Time frame: Up to Week 25
Number of Participants With Any Adverse Events and Serious Adverse Events
An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An Serious Adverse Events (SAEs) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect.
Time frame: Up to Week 29
A total of 1987 participants were recruited into the study across 164 centers in 25 countries. This study was conducted from 12 Nov 1998 to 01 Apr 2004.
| Milestone | Capecitabine | 5-Fluorouracil + Leucovorin |
|---|---|---|
| Started | 1004 | 983 |
| Completed | 834 | 860 |
| Not completed | 170 | 123 |
| Withdrew: Adverse event | 112 | 75 |
| Withdrew: Death | 4 | 6 |
| Withdrew: Lack of efficacy | 17 | 15 |
| Withdrew: Violation of selection criteria at entry | 13 | 9 |
| Withdrew: Other protocol violation | 1 | 0 |
| Withdrew: Refused treatment | 15 | 16 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Administrative/other reasons | 7 | 1 |
Participants with disease-free survival were reported. Disease-free survival was assessed as the number of days between randomization and the first time at which relapse, a new occurrence of colon cancer, or death was recorded, or the last time at which a participant was known to be disease free (censoring time).
| Participants | Capecitabine | 5-Fluorouracil + Leucovorin |
|---|---|---|
| Disease-free Survival | 656 | 603 |
Participants with relapse-free survival were reported. Relapse-free survival was assessed as the number of days between randomization and the first time at which relapse, a new occurrence of colon cancer, or death was recorded, or the last time at which a participants was known to be disease free (censoring time), excluding deaths that were not related to treatment or to disease progression.
| Participants | Capecitabine | 5-Fluorouracil + Leucovorin |
|---|---|---|
| Relapse-Free Survival | 677 | 621 |
Participants with overall survival were reported. Overall survival was assessed as the number of days between randomization and death or the last time at which a participant was known to be alive (censoring time).
| Participants | Capecitabine | 5-Fluorouracil + Leucovorin |
|---|---|---|
| Overall Survival | 804 | 756 |
Global health status was assessed as a sub scale of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. It was scored on a scale of 0-100; where higher score indicates better quality of life. Wherever the scores for the participants were not available, the last value carried forward (LVCF) were used.
| Score on a scale | Capecitabine | 5-Fluorouracil + Leucovorin |
|---|---|---|
| Mean Change From Baseline in Global Health Status at Week 25 | 2.1 ± 0.80 | 2.6 ± 0.78 |
Laboratory abnormalities were categorized according to the National Cancer Institute of Canada Common Toxicity Criteria (NCIC - CTC) grading system (May 1991 revised) as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (life- threatening). Participants with abnormalities in hemoglobin, granulocytes, lymphocytes, neutrophils, neutrophils/granulocytes, platelets, white blood cell, potassium, serum creatinine, sodium, total bilirubin, alanine transaminase, aspartate aminotransferase, alkaline phosphatase, calcium (hyper), and calcium (hypo) with Grades 1-4 were presented.
| Participants | Capecitabine | 5-Fluorouracil + Leucovorin |
|---|---|---|
| Alanine transaminase | 327 | 333 |
| Aspartate aminotransferase | 300 | 288 |
| Alkaline Phosphatase | 334 | 289 |
| Calcium (Hyper) | 67 | 68 |
| Calcium (Hypo) | 150 | 112 |
| Granulocytes | 20 | 43 |
| Hemoglobin | 691 | 650 |
| Lymphocytes | 778 | 744 |
| Neutrophils | 308 | 596 |
| Neutrophils/Granulocytes | 316 | 612 |
| Platelets | 182 | 160 |
| Potassium | 209 | 156 |
| Serum Creatinine | 157 | 138 |
| Sodium | 189 | 184 |
| Total Bilirubin | 501 | 185 |
| White blood cell | 220 | 409 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An Serious Adverse Events (SAEs) is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect.
| Participants | Capecitabine | 5-Fluorouracil + Leucovorin |
|---|---|---|
| All adverse events | 910 | 885 |
| Serious adverse events | 181 | 182 |
Collected over Up to Week 29. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Capecitabine | — | 181/995 (18.2%) | 838/995 (84.2%) |
| 5-Fluorouracil + Leucovorin | — | 182/974 (18.7%) | 847/974 (87%) |
| Event | Capecitabine | 5-Fluorouracil + Leucovorin |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 58/995 | 34/974 |
| *Stomatitis allGastrointestinal disorders | 4/995 | 25/974 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/995 | 17/974 |
| Abdominal painGastrointestinal disorders | 9/995 | 10/974 |
| Small intestinal obstructionGastrointestinal disorders | 7/995 | 10/974 |
| Deep vein thrombosisVascular disorders | 10/995 | 6/974 |
| Intestinal obstructionGastrointestinal disorders | 9/995 | 3/974 |
| DehydrationMetabolism and nutrition disorders | 8/995 | 7/974 |
| VomitingGastrointestinal disorders | 5/995 | 7/974 |
| NeutropeniaBlood and lymphatic system disorders | 3/995 | 7/974 |
| Event | Capecitabine | 5-Fluorouracil + Leucovorin |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 437/995 | 610/974 |
| Palmar-plantarSkin and subcutaneous tissue disorders | 593/995 | 85/974 |
| Stomatitis allGastrointestinal disorders | 218/995 | 574/974 |
| NauseaGastrointestinal disorders | 334/995 | 459/974 |
| Erythrodysaesthesia syndrome AlopeciaSkin and subcutaneous tissue disorders | 63/995 | 218/974 |
| VomitingGastrointestinal disorders | 147/995 | 199/974 |
| FatigueGeneral disorders | 155/995 | 150/974 |
| Abdominal painGastrointestinal disorders | 133/995 | 149/974 |
| AnorexiaMetabolism and nutrition disorders | 90/995 | 104/974 |
| ConstipationGastrointestinal disorders | 86/995 | 103/974 |
All randomized population included all participants who were randomized to one of the two treatment arms, regardless of whether they received any study medication.
| Age, Continuous(Years) | Capecitabine | 5-Fluorouracil + Leucovorin | Total |
|---|---|---|---|
| Median | 62.0 (25 to 80) | 63.0 (22 to 82) | 62.0 (22 to 82) |
| Sex/Gender, Customized(Participants) | Capecitabine | 5-Fluorouracil + Leucovorin | Total |
|---|---|---|---|
| Female | 461 | 451 | 912 |
| Male | 542 | 532 | 1074 |
| Missing | 1 | 0 | 1 |
Showing the first 100 of 133 sites across 14 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 1998, a primary completion of Apr 2004 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 12 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Capecitabine